By Fineline Cube 
Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set to acquire the rights to Caprelsa (vandetanib) from Sanofi (NASDAQ: SNY) in more than 50 countries. Caprelsa, a kinase inhibitor approved by the U.S. FDA in April 2011, is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in adults and children aged 5 years and older.
Esteve’s Strategic Move in Rare Diseases
In April 2024, Esteve acquired a company specializing in rare and ultra-rare diseases in endocrinology and onco-endocrinology, adding three new drugs to its pipeline for the treatment of endogenous Cushing’s syndrome and adrenocortical carcinoma. Building on this expansion, the company further licensed a biologic for treating severe primary insulin-like growth factor-1 (IGF-1) deficiency in patients aged 2 to 18. This biologic was recently approved as a standard adjuvant therapy for high-grade, resectable, non-metastatic osteosarcoma in patients aged 2 to 30.-Fineline Info & Tech